<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20180201105400Z</creation_date><modification_date>D:20180724154800Z</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-18-1299_h_dec_0.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 23.8.2018c(2018)5718 (final)</p></section><section><header>commission implementing decisionof 23.8.2018
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;yescarta - axicabtagene ciloleucel&quot;, an orphan 
 medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 23.8.2018
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;yescarta - axicabtagene ciloleucel&quot;, an orphan 
 medicinal product for human use</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10(2) thereof,having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products
 2, and in particular article 5(12) thereof,
 having regard to regulation (ec) no 1394/2007 of the european parliament and of the 
 council of 13 november 2007 on advanced therapy medicinal products and amending 
 directive 2001/83/ec and regulation (ec) no 726/2004
 3,having regard to the application submitted by kite pharma eu b.v., on 17 august 2017, 
 under article 4(1) of regulation (ec) no 726/2004,
 having regard to the opinions of the european medicines agency, formulated on 28 june 
 2018 by the committee for medicinal products for human use and on 19 july 2018 by the 
 committee for orphan medicinal products,
 whereas:
 (1)
 commission decisions c(2014)10041(final) and c(2015)7024(final), adopted in 
 accordance with regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products designated &quot;autologous 
 t cells transduced with retroviral vector encoding an anti-cd19 cd28/cd3-zeta 
 chimeric antigen receptor&quot; as an orphan medicinal product.
 (2)
 the medicinal product &quot;yescarta - axicabtagene ciloleucel&quot; complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of the 
 council of 6 november 2001 on the community code relating to medicinal products 
 for human use
 4 and in regulation (ec) no 1394/2007.1oj l 136, 30.4.2004, p. 1.2oj l 18, 22.1.2000, p. 1.3oj l 324, 10.12.2007, p. 121.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(3)it is therefore appropriate to authorise its placing on the market.
 (4)
 the committee for medicinal products for human use considered that &quot;axicabtagene 
 ciloleucel&quot; is a new active substance.
 (5)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 has adopted this decision:
 article 1the marketing authorisation provided for in article 3 of regulation (ec) no 726/2004 is granted for the orphan medicinal product &quot;yescarta - axicabtagene ciloleucel&quot;, the 
 characteristics of which are summarised in annex i to this decision. &quot;yescarta - axicabtagene 
 ciloleucel&quot; shall be registered in the community register of medicinal products under number 
 eu/1/18/1299.
 article 2the marketing authorisation concerning the medicinal product referred to in article 1 shall be subject to compliance with the conditions set out in annex ii and, in particular, with those 
 relating to manufacture and importation, control and issue.
 article 3the labelling and package leaflet concerning the orphan medicinal product referred to in article 1 shall conform to annex iii.
 article 4the period of validity of the authorisation shall be five years from the date of notification of this decision.
 article 5this decision is addressed to kite pharma eu b.v., science park 408, 1098 xh amsterdam, nederland.
 done at brussels, 23.8.2018
 for the commissionxavier prats monn√©
 director-general
 4oj l 311, 28.11.2001, p. 67.</p></section></body></xml>